One of the key factors affecting delivery of drugs to the lungs is particle size. This is relevant for both dry powder inhaler (DPI) and suspension pressurized metered dose inhaler (pMDI) formulations. Depending upon the specific airway target site, the particle size can vary slightly but generally, an aerodynamic particle size distribution (PSD) of 1-6 µm is required for successful inhalation therapy.
High pressure homogenization as an alternative methodology to micronization for obtaining effective inhalation particles
Case studies for the industrial manufacture of inhalation grades of fluticasone propionate and mometasone furoate monohydrate.